New hope for liver cancer patients with damaged livers?

NCT ID NCT05622071

Completed Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called tislelizumab in 50 people with advanced liver cancer who also have moderate liver damage (Child-Pugh B). The goal was to see if the drug could shrink tumors. Tislelizumab works by helping the immune system attack cancer cells. The study took place in France and included people who may or may not have had prior treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA BY BCLC STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA BY BCLC STAGE

Contacts and locations

Show contact details

Locations

CHRU Strasbourg

Strasbourg, France
CHU Angers

Angers, France
CHU Beaujon

Clichy, France
CHU La Croix Rousse

Lyon, France
CHU Saint Eloi

Montpellier, France
Centre Eugene Marquis

Rennes, France
Hôpital Avicenne

Bobigny, France
Hôpital Michallon

Grenoble, France
Hôpital Saint Joseph

Marseille, France
Institut Paoli Calmette

Marseille, France